Although LAM remains a progressive disease, treatment with mTOR inhibitors, particularly Sirolimus, has been shown to slow down the decline in the lung function, reduce respiratory impairment, improve the quality of life and physical performance, and lower the VEGF-D levels [2,4]. Here, VEGFD is linked to lymphangioleiomyomatosis.